Hepatic Disease in Patients With HIV

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/13/21 (What's New)


  • Studies of hydroxymethylglutaryl-CoA reductase inhibitors (statins) have reported some evidence of reductions in serum ALT[Gómez-Domínguez 2006; Hatzitolios 2004; Athyros 2006; Abel 2009]
  • The US National Lipid Association Statin Liver Safety Task Force has concluded that statin therapy is safe in patients with NAFLD and dyslipidemia[Bays 2014]
  • The AASLD and EASL guidelines recommend the use of statins for treatment of dyslipidemia in patients with NAFLD and NASH[AASLD NAFLD; EASL NAFLD]

Action required